FILING ANALYSIS · THURSDAY, NOVEMBER 5
GYRE THERAPEUTICS, INC. GYRE — 8-K: Results of Operations and Financial Condition
neutral
Gyre Therapeutics reported Q3 revenue of $32.9 million and affirmed full-year revenue guidance, with several pipeline developments and upcoming milestones, including potential launch of F351 in China in 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →